Tag Archives: NASH

Terns Pharmaceuticals Announces Completion and Positive Results from Phase I Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

Terns Pharmaceuticals, Inc., has announced positive results from its completed Phase I single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, being developed for the treatment of non-alcoholic steatohepatitis (NASH).
[Terns Pharmaceuticals]
Press Release

Continue reading “Terns Pharmaceuticals Announces Completion and Positive Results from Phase I Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH”

Bookmark

No account yet? Register

0
Share

Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase IIa Clinical Trial of TERN-101 in Development for NASH

Terns Pharmaceuticals, Inc., has announced that it has dosed the first patient in the LIFT study, a Phase IIa clinical trial of TERN-101, a liver-selective farnesoid X receptor agonist, the company’s lead development candidate for the treatment of non-alcoholic steatohepatitis (NASH).
[Terns Pharmaceuticals]
Press Release

Continue reading “Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase IIa Clinical Trial of TERN-101 in Development for NASH”

Bookmark

No account yet? Register

0
Share

Human Hepatic In Vitro Models Reveal Distinct Anti-NASH Potencies of PPAR Agonists

Investigators reproduced key non-alcoholic steatohepatitis (NASH) characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 cells to multiple factors that play a role in the onset of NASH.
[Cell Biology and Toxicology]
Abstract

Continue reading “Human Hepatic In Vitro Models Reveal Distinct Anti-NASH Potencies of PPAR Agonists”

Bookmark

No account yet? Register

0
Share

An Endoplasmic Reticulum Stress‐MicroRNA‐26a Feedback Circuit in Nonalcoholic Fatty Liver Disease

Scientists identified a negative feedback loop comprising hepatic endoplasmic reticulum (ER) stress and micro RNA (miRNA)‐26a in nonalcoholic fatty liver disease pathogenesis. Combining miRNA dot blot array and quantitative PCR, they found that miR‐26a was specifically induced by ER stress in liver cells.
[Hepatology]
Abstract

Continue reading “An Endoplasmic Reticulum Stress‐MicroRNA‐26a Feedback Circuit in Nonalcoholic Fatty Liver Disease”

Bookmark

No account yet? Register

0
Share

Hepatic HuR Modulates Lipid Homeostasis in Response to High-Fat Diet

Hepatocyte-specific HuR knockout reduced the expression of APOB, UQCRB, and NDUFB6 in mice, reducing liver lipid transport and ATP synthesis, and aggravating high-fat diet-induced non-alcoholic fatty liver disease.
[Nature Communications]
Full Article

Continue reading “Hepatic HuR Modulates Lipid Homeostasis in Response to High-Fat Diet”

Bookmark

No account yet? Register

0
Share
Share